Allergan
Allergan says its double chin correction therapy Belkyra gets positive opinion from Swedish regulators
July 4, 2016Research and Development, Sales and Marketing Allergan, Belkyra, Botox, EU, Sweden, double chin, drug trial
Botox maker Allergan (NYSE: AGN) said it has received a positive opinion from the Swedish Medical Products Agency for its …
Mayne Pharma to buy a portfolio of Teva’s generic drugs for $652 million
June 29, 2016Research and Development, Sales and Marketing Allergan, Deals, Mayne Pharma, Teva, generics, merger and acquisition
Australia’s Mayne Pharma Group Ltd (ASX: MYX) said it will acquire US generic products from Israel-based drugmaker Teva Pharmaceuticals (NYSE: …
FDA approves expanded label for Allergan’s Avycaz
June 24, 2016Medical Communications, Research and Development, Sales and Marketing Allergan, Avycaz, FDA, expanded label
Allergan (NYSE: FDA) has announced that the US Food and Drug Administration (FDA) has approved its supplemental new drug application …
Impax to acquire Teva, Allergan generic drugs for $586 million
June 22, 2016Research and Development, Sales and Marketing Allergan, Impax, Teva, generics
Impax Laboratories (NASDAQ: IPXL) has announced that it has entered into agreements with Teva and affiliates of Allergan to acquire …
FDA approves Allergan hypertension fixed-dose combo, Byvalson
June 7, 2016Manufacturing and Production, Research and Development, Sales and Marketing Allergan, FDA, US, angiotensin ii, approval, beta blocker, byvalson, hypertension, nebivolol, valsartan
Allergan has announced that the US Food and Drug Administration (FDA) has approved its fixed-dose combination, Byvalson (nebivolol and valsartan), …
Allergan’s chronic eye disease treatment meets endpoints in pivotal trials
May 17, 2016Manufacturing and Production, Sales and Marketing Allergan, FDA, chronic eye disease
Allergan has announced positive top line results from two pivotal late-stage trials for the first and only neurostimulation device for …
Weekly Movers: Teva, Midatech, Allergan…
May 16, 2016Research and Development, Sales and Marketing Allergan, Ariad Pharmaceuticals, Lundbeck, Midatech Pharma, Stock, Teva Pharmaceutical, markets
We have hit the tail end of the earnings season and the near last batch of movers follow result pronouncements …
Allergan to buy back $10 billion of stock, Q1 earnings rise
May 11, 2016Research and Development, Sales and Marketing Allergan, Buy Back, Financial, Q1, earnings, results, revenue
Botox-maker Allergan (NYSE: AGN) said it plans to buy back as much as $10 billion in stock after completing the …
Phase III trial meets primary endpoint for Allergan’s fibroid treatment
May 9, 2016Manufacturing and Production, Research and Development, Sales and Marketing Allergan, fibroid, phase 3, phase III, ulipristal, ulipristal acetate, uterine fibroid
Allergan (NYSE: AGN), in collaboration with Gedeon Richter, has announced positive results from a pivotal Phase III trial evaluating the …
Allergan launches Crestor generic in the US
May 3, 2016Manufacturing and Production, Research and Development, Sales and Marketing Allergan, AstraZeneca, Crestor, FDA, FDA Approval, cholesterol, generic, patent, patent expiry, sales
Allergan has received FDA approval on the generic version of AstraZeneca’s high cholesterol drug, Crestor (rosuvastatin), and has become the …
Allergan breaks ground on $200 million expansion at Texas site
April 26, 2016Manufacturing and Production Allergan, doubling, expansion, eye care, facility, investment, manufacturing, size, texas, waco
Allergan (NYSE: AGN) has broken ground on a $200 million expansion at its manufacturing facility in Waco, Texas. The expansion …
Shire reassures Baxalta acquisition on track in the aftermath of Pfizer-Allergan breakup
April 7, 2016Business Services, Sales and Marketing AbbVie, Allergan, Baxalta, Deals, Financial, Merger & Acquisition, Pfizer, Shire
Ireland-headquartered Shire Plc (LSE: SHP) has reassured its $32-billion merger deal with US-based Baxlata (NYSE: BXLT) remains on track in …
Allergan to partner with Heptares in Alzheimer’s disease collaboration
April 7, 2016Manufacturing and Production, Research and Development, Sales and Marketing Allergan, Alzheimer's, Heptares, R&D, collaboration, commercialisation, h1, h4, neurological disorders, partnership, research and development, treatments
Bouncing back quickly from the collapse of the collapse of the Pfizer inversion deal, Allergan (NYSE:AGN) has announced a new …
5 things to know about the Pfizer/Allergan inversion collapse
April 6, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 5, 5 things, Allergan, Pfizer, collapse, inversion, reasons
The end came very quickly for the Pfizer/Allergan $160 billion deal once the US Treasury Department announced a new set …
Pfizer to call off $160 billion merger with Allergan
April 6, 2016Business Services, Research and Development, Sales and Marketing Allergan, Pfizer, deal, legal, merger and acquisition, regulation
US pharma giant Pfizer Inc (NYSE: PFE) has decided to terminate the $160 billion merger with Botox-maker Allergan Plc (NYSE: …
Latest content
FibroFind appoints Lee Borthwick as CEO
